Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients

• Published in: European journal of cancer & clinical oncology Vol. 22; no. 3; pp. 257 - 263
• Main Authors: Gouyette, Alain, Apchin, Annie, Foka, Maria, Richard, Jean-Marie
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.03.1986; New York, NY Pergamon Press
• Subjects: Adult; Antineoplastic agents; Biological and medical sciences; Cisplatin - administration & dosage; Cisplatin - metabolism; Cisplatin - therapeutic use; General aspects; Half-Life; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - metabolism; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Kinetics; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Platinum - blood; Platinum - urine; Antineoplastic agent; Human; Intravenous administration; Head and neck; ENT disease; Tumor; Intraarterial administration; Pharmacokinetics; Platinum II Complexes
• ISSN: 0277-5379
• DOI: 10.1016/0277-5379(86)90389-5

After administration of cisplatin (50 mg/m 2 on days 1 and 2) by intra-arterial or intravenous infusions over 1 or 6 hr to a total of 24 patients with head and neck cancer, the main pharmacokinetic parameters of platinum were determined according to a multicompartmental analysis. Elimination half-life of total platinum is >3 days, the amount of platinum recovered in the urine over 7 days accounting for 15–50% of the administered dose. The half-life of filterable platinum species was calculated from the urinary excretion data: 39 ± 17 min (i.a./1 hr), 37 ± 24 min (i.a./6 hr), 58 ± 17 min (i.v./1 hr) and 51 ± 22 min (i.v./6 hr). Biopsies of the tumor were also analyzed on day 3 for their platinum content. The mean concentrations of platinum in biopsies were: 2.72 μ g/g (i.a./1 hr), 3.89 μ g/g (i.a./6 hr), 1.27 μ g/g (i.v./1 hr) and 1.38 μ g/g (i.v./6 hr). Tumor regression, based upon clinical and histological data, was only moderate after this single chemotherapy course.